HEALED Consortium was successful in obtaining DTIF assistance of €6.8 million as part of a three-year, €10.5 million effort to create new cell treatments for cancer. RemedyBio as the project leader, aCGT Vector DAC, Trinity College Dublin & St James’s Hospital and the SFI Centre for Research Training (CRT) in Genomics Data Science at NUIG make up the partnership.
The objective is to enable a novel, revolutionary immunotherapy to treat tumors that are currently incurable. The Disruptive Technologies Innovation Fund (DTIF) is managed and funded through the Department of Enterprise and Innovation (DBEI) in Ireland.
More in the original announcement in Pharma’s Almanac in the link below.